RNA Interference News and Research

RSS

Protein missing in fragile X syndrome acts as a molecular toggle switch in brain cells

New research shows how the protein missing in fragile X syndrome - the most common inherited form of intellectual disability - acts as a molecular toggle switch in brain cells.

10 Jun 2011

Scientists uncover new role for key cancer protein

Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors.

10 Jun 2011

Microscopic worms in space

A space flight by millions of microscopic worms could help us overcome the numerous threats posed to human health by space travel. The Caenorhabditis elegans (C. elegans) have also given experts an insight into how to block muscle degradation in the sick and elderly.

2 Jun 2011

Tumor necrosis factor can suppress inflammation, treat rheumatoid arthritis

A new study by rheumatologists at Hospital for Special Surgery in New York has shown that a powerful pro-inflammatory protein, tumor necrosis factor, can also suppress aspects of inflammation.

23 May 2011

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.

19 May 2011

Novel topically-applied molecular microbicide protects women against HIV infection

Using a technique that silences genes promoting infection, researchers have developed a novel, topically-applied molecular microbicide capable of preventing HIV transmission.

17 May 2011

Benitec raises AU$8 million for gene silencing therapeutics

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, today announced its fully underwritten AU$8 million renounceable rights issue, incorporating an entitlement offer and a shortfall offer, had successfully closed oversubscribed.

17 May 2011

PVT1 gene may help reduce diabetic nephropathy

A gene called PVT1 may help reduce the kidneys ability to filter blood, leading to kidney disease, kidney failure and death, according to a study published today by researchers at the Translational Genomics Research Institute.

25 Apr 2011

New method allows single microchip to screen tens of thousands of genes simultaneously

RNA interference technology, which is used in cell biology, has revolutionised functional research of the gene products in the last ten years. VTT Technical Research Centre of Finland has developed a method which allows a single microchip to be used to screen the functions of tens of thousands of genes simultaneously by means of RNA interference.

20 Apr 2011

Scientists identify novel small molecules that block human tumor cell growth

Researchers from the Cancer Institute at NYU Langone Medical Center have identified three novel small molecules that interrupt a crucial cellular communication pathway that regulates many aspects of development and cancer.

15 Apr 2011

Researchers temporarily turn off essential gene using RNAi technology

One way of discovering a gene's function is to switch it off and observe how the loss of its activity affects an organism. If a gene is essential for survival, however, then switching it off permanently will kill the organism before the gene's function can be determined. Researchers at Cold Spring Harbor Laboratory (CSHL) have overcome this problem by using RNA interference (RNAi) technology to temporarily turn off any essential gene in adult mice and then turn it back on before the change kills the animals.

15 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

30 Mar 2011

Molecular Therapy journal publishes Mirna's new tumor suppressor miRNA mimics data

Mirna Therapeutics, Inc. announced today the publication of new results in the journal Molecular Therapy demonstrating how a neutral lipid emulsion facilitates the systemic delivery of tumor suppressor miRNA mimics and reduces the tumor burden in the lungs of mice.

24 Mar 2011

Rxi's new RNAi preclinical data to be presented at Keystone conference

RXi Pharmaceuticals Corporation, a recognized leader in RNA interference based therapeutic discovery and development, today announced that new preclinical data using proprietary self-delivering RNAi compounds, including RXI-109, will be presented at the Keystone Symposia's Mechanism and Biology of Silencing conference being held March 20-25, 2011 in Monterey, California.

22 Mar 2011

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

Benitec Limited (ASX:BLT), a company involved in RNA-based gene silencing for human therapeutics, announced that the City of Hope research hospital in Duarte, California is planning to initiate a second small Phase I/II study using Benitec’s DNA-directed RNA interference (ddRNAi) technology in lymphoma patients carrying the HIV virus. The aim of the study is to optimize the treatment by modifying a range of clinical parameters.

21 Mar 2011

Scientists identify strategy for targeted molecular therapy in liver cancer

In a research study appearing in the journal Cancer Cell on March 14, scientists from Cold Spring Harbor Laboratory and four other institutions have identified a strategy for targeted molecular therapy in liver cancer, which currently has limited treatment options and one of the worst one-year survival rates of any cancer type.

15 Mar 2011

Scientists develop new method that uncovers combined effects of genes

Scientists at the European Molecular Biology Laboratory and the German Cancer Research Centre, both in Heidelberg, Germany, have developed a new method that uncovers the combined effects of genes.

8 Mar 2011

Benitec strengthens patent position in RNAi

Benitec Limited (ASX: BLT), (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, is pleased to announce that the United States Patent and Trademark Office (USPTO) has today indicated that it is issuing the Re-examination Certificate, the formal final step in the USPTO’s confirmation of patentability of claims in the key ‘099 Graham Patent [US Patent No. 6,573,099] "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene", the wide-ranging platform technology patent covering the use of expressed RNA interference (RNAi) in human therapeutic applications.

17 Feb 2011

Viral infection of Leishmania leads to increased pathogenicity

A parasite and a virus may be teaming up in a way that increases the parasite's ability to harm humans, scientists at the University of Lausanne in Switzerland and Washington University School of Medicine in St. Louis report this week in Science.

11 Feb 2011